title: Review article: new drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitis.
abstract: BACKGROUND
  Treatment options for ulcerative colitis (UC) are expanding with the development of novel drug formulations and dosing regimens and new chemical entities. Although the goals of medical therapy for UC remain unchanged, that is to induce and to maintain remission, focus has also centred on improving patient compliance, modifying the natural course of disease and healing the mucosa.
  
  
  OBJECTIVE
  To examine novel formulations, new chemical entities and novel therapeutic approaches to the management of UC.
  
  
  METHODS
  Searches for all studies related to UC treatment in Medline and abstracts from major national and international meetings published in the last 10 years.
  
  
  RESULTS
  5-Aminosalicylic acids (5-ASA) remain the standard first-line treatment for patients with mild to moderately active UC. New formulations with altered delivery, and new dosing regimens have demonstrated possible improvements in efficacy compared with historically available preparations and dosing patterns. Once-daily dosing, micropellet formulations,and high-dose tablets offer enhanced efficacy and improved compliance. 5-ASA is now recognized as a ligand for peroxisome proliferator activated receptor-gamma (PPAR-gamma) and it has a role as a chemo-preventive agent in long-standing UC. New colonic release corticosteroid formulations help to limit systemic toxicity; turmeric, tacrolimus and infliximab have shown promising results. New anti-inflammatory targeted therapies include an anti-CD3 antibody, selective integrin blockers, anti-IL-2 antibody and PPAR-gamma agonists.
  
  
  CONCLUSIONS
  The evolution of novel oral 5-ASA formulations and dosage regimens,and recent development of new molecules have expanded the therapeutic armamentarium of UC.
authors.affiliation: St Mark's Hospital, London, UK.
authors.forename: S C
authors.initials: SC
authors.lastname: Ng
authors.forename: M A
authors.initials: MA
authors.lastname: Kamm
mesh_terms: D000636:Aminosalicylic Acids / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001685:Biological Factors / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D004334:Drug Administration Schedule; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans
chemical_list: D000636:Aminosalicylic Acids; D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001685:Biological Factors; D003692:Delayed-Action Preparations; D005765:Gastrointestinal Agents